Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site mass12.07.03.010; 08.02.03.0090.000689%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.005640%Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.0130.001535%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.001003%
Interstitial lung disease22.01.02.003; 10.02.01.0330.001567%Not Available
Intestinal dilatation07.02.02.0100.000783%Not Available
Intestinal obstruction07.13.01.0020.008146%Not Available
Intestinal perforation07.04.06.0020.001567%Not Available
Intestinal stenosis07.13.01.0030.006736%Not Available
Intestinal ulcer07.04.06.0030.000783%Not Available
Iridocyclitis06.04.03.0010.000627%Not Available
Iritis10.02.01.022; 06.04.03.002--Not Available
Iron deficiency14.13.02.002--Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.0020.001880%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.002318%Not Available
Jaundice cholestatic09.01.01.0050.001003%Not Available
Joint effusion15.01.02.0050.000470%
Joint stiffness15.01.02.0030.001003%Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.001410%Not Available
Kidney transplant rejection20.01.02.009; 12.02.10.004; 10.02.03.0030.000470%Not Available
Lactose intolerance07.17.01.003; 14.02.02.0010.000313%Not Available
Large intestinal ulcer07.04.06.0040.000470%
Large intestine perforation07.04.06.005; 12.02.03.0050.000627%
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000470%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.001880%
Leukaemia16.01.03.001; 01.10.03.0010.000313%
Leukocytosis01.02.01.0020.000627%
Leukoencephalopathy17.13.02.0030.000313%
Leukopenia01.02.02.0010.008585%Not Available
Lip dry07.06.01.0030.000313%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene